April 24th 2024
The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Sarcopenic Obesity Associated with Worse OS Outcomes in Endometrial Cancer
October 28th 2021While some studies have found that obesity provides a survival advantage in certain cancers, sarcopenia obesity was found to be associated with worse survival outcomes in patients with endometrial cancer.
Read More
Promising Safety/Efficacy Signals Shown With Lenvatinib Plus Weekly Paclitaxel in Endometrial Cancer
October 14th 2021Currently, no FDA-approved therapies are available to address the need of patients with advanced/recurrent endometrial cancer, underscoring a need to develop novel strategies like the combination of lenvatinib and weekly paclitaxel.
Read More
Racial Disparities Persist Among Women With Endometrial Cancers in Equal-Access Healthcare Systems
October 14th 2021Despite researchers compiling data from an equal-access system and adjusting for age, diagnosis period, tumor stage, tumor histology/grade, and whether the patient had adjuvant treatment, the overall survival disparity between Black and White women with endometrial cancer persisted.
Read More
High Responses to Dostarlimab in Endometrial Cancer Linked to TMB-H Status
September 16th 2021High responses to single-agent dostarlimab-gxly were seen in patients with endometrial cancer who had a high tumor mutational burden, irrespective of mismatch repair or microsatellite stability status.
Read More
Westin Explains the Need for Novel Therapies in the Endometrial Cancer Space
August 14th 2021Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.
Watch
FDA Accepts sBLA for Pembrolizumab Monotherapy for Endometrial Cancer
August 10th 2021The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Read More
NRG-GY012 Study in Recurrent or Metastatic Endometrial Cancer Adds Treatment Arms
July 29th 2021In an interview with Targeted Oncology, Bobbie J. Rimel, MD, discussed the phase 2 NRG-GY012 results and the next step for cediranib plus olaparib as treatment of recurrent or metastatic endometrial cancer.
Read More
FDA Approves Lenvatinib/Pembrolizumab for Select Patients With Advanced Endometrial Cancer
July 22nd 2021The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.
Read More